Prolactin Blood Test: Interpretation, Confounders, and the Dopamine-GH Connection

Prolactin is one of those markers that gets ordered, comes back high, and then sits on the file for months because nobody is quite sure what to do with it. Sometimes the elevation is meaningful. Sometimes it's the blood draw itself. Sometimes it's a laboratory artefact — a heavy, biologically inert molecule the immunoassay mistakes for the real thing.

This guide walks through what prolactin actually is, why timing and stress matter so much, the medications that quietly drive it up, and the sex-specific symptom patterns that distinguish meaningful elevations from incidental ones.

What prolactin is and where it comes from

Prolactin is a single-chain polypeptide hormone secreted by the lactotroph cells of the anterior pituitary gland. Unlike most pituitary hormones, which sit under positive hypothalamic drive, prolactin is held down by tonic inhibition from dopamine released by tuberoinfundibular neurons. Cut the stalk, block the receptor, or deplete dopamine — and prolactin rises immediately.

Its named role is lactation. Its biological reach is wider: it modulates reproductive function, immune signalling, osmoregulation, and — relevant to anyone tracking the growth hormone axis — interacts with the somatotroph population in the same pituitary lobe.

Reference ranges by sex, cycle phase, and age

Most Australian labs report prolactin in mIU/L (some in ng/mL — multiply ng/mL by ~21 to convert). Typical adult ranges:

• Men: ~85–325 mIU/L (4–15 ng/mL)
• Non-pregnant women, follicular phase: ~100–500 mIU/L (5–25 ng/mL)
• Luteal phase: slightly higher, up to ~600 mIU/L
• Pregnancy: rises progressively, reaching 4000–8000 mIU/L by the third trimester
• Lactation: highly variable, suckling-driven spikes
• Post-menopausal women: drift downward toward male ranges

Paediatric ranges are higher in early infancy and settle toward adult ranges by mid-childhood. Reference intervals vary by assay platform — always compare against the range printed on the report you're holding, not a range you read elsewhere.

Why sampling timing matters more than people think

Prolactin has a strong diurnal pattern. Levels peak during sleep (typically 4–6 hours after sleep onset), remain elevated on waking, and decline through the morning to reach their daily nadir between roughly 10am and noon.

This matters because:

1. A sample drawn at 7am may sit ~50% higher than the same person's sample at 11am.
2. Acute stress raises prolactin. The needlestick itself can push values up by 30–50% in some people — the so-called venepuncture spike.
3. Anything that triggers a stress response in the hour before sampling — running late, an argument, a chest pain workup, even a particularly bad parking experience — feeds the same effect.
4. Recent nipple stimulation, breast examination, or vigorous exercise all transiently elevate prolactin.

Practical sampling protocol

• Fast overnight (water permitted).
• Schedule the draw mid-to-late morning (ideally 10am–noon), at least 2–3 hours after waking.
• Sit quietly for 15–20 minutes before the draw.
• Avoid breast examination or nipple stimulation that morning.
• If a borderline-elevated result is found, repeat under controlled conditions before any imaging or referral cascade — current Endocrine Society guidance considers a single elevated reading insufficient when the patient is asymptomatic.

For broader interpretation logic across pituitary hormones, the layered approach in our thyroid panel walkthrough applies just as well here.

Macroprolactin — the result that lies

Here's the trap that catches more clinicians than any other prolactin pitfall. Prolactin circulates in three forms:

• Monomeric prolactin (~23 kDa) — the biologically active form.
• Big prolactin (~50 kDa) — a dimer.
• Big-big prolactin / macroprolactin (~150 kDa) — prolactin bound to immunoglobulin G, forming a complex that is too large to leave the circulation and is largely biologically inert.

The catch: most standard immunoassays measure all three indiscriminately. A patient with high circulating macroprolactin can register a "high prolactin" reading while their bioactive prolactin is completely normal — and they will have no symptoms whatsoever.

Prevalence is not trivial. Work by Vilar and colleagues on macroprolactin prevalence and others estimates that macroprolactin accounts for 10–25% of all hyperprolactinaemia cases referred for evaluation, depending on the population sampled.

When to suspect it

• "High prolactin" with no symptoms (no galactorrhoea, normal menses, normal libido and erectile function).
• Modest elevations (typically 600–2000 mIU/L) that don't track with clinical findings.
• Discordance between repeated measurements.

How to check

Ask the lab for polyethylene glycol (PEG) precipitation. PEG precipitates the macroprolactin-IgG complex; the supernatant is reassayed. If recovery is <40%, macroprolactin is the dominant form and the original result was misleading. Many Australian labs will run this on request but won't do it automatically.

Causes of true hyperprolactinaemia

Once macroprolactin is excluded and the elevation is genuine, the differential is broad. The major categories:

1. Pituitary causes

• Prolactinoma — the commonest pituitary adenoma. Microprolactinomas (<10 mm) typically present with prolactin in the 2000–5000 mIU/L range; macroprolactinomas (>10 mm) often run >5000 mIU/L and can exceed 10,000.
• Stalk effect — any pituitary or parasellar mass that compresses the pituitary stalk interrupts dopaminergic inhibition, producing modest elevations (typically <2000 mIU/L) regardless of the lesion's secretory profile.
• Empty sella, hypophysitis, infiltrative disease — uncommon but worth considering when other findings don't fit.

2. Medications — the single most common cause in practice

Any drug that interferes with dopamine signalling can drive prolactin up. The usual suspects:

• Antipsychotics — particularly risperidone, paliperidone, amisulpride, and haloperidol, which are strong D2 antagonists. Aripiprazole is typically prolactin-sparing or even prolactin-lowering. Clozapine, quetiapine and olanzapine sit somewhere in between.
• Antiemetics — metoclopramide and domperidone are potent prolactin elevators despite their everyday clinical use.
• Opioids — both prescription and recreational. Methadone is particularly notable.
• Oestrogens — combined oral contraceptives and high-dose menopausal therapy can produce modest elevations.
• Verapamil — a calcium-channel blocker that uniquely (among its class) raises prolactin.
• Selective serotonin reuptake inhibitors — small effect, usually clinically irrelevant.
• Tricyclics and MAOIs — variable.

Medication-induced elevations are usually modest (200–2000 mIU/L) but can occasionally exceed 5000 with antipsychotics. The key diagnostic step is a drug holiday where clinically safe — if prolactin normalises within 72 hours of stopping the agent, the case is closed.

3. Hypothyroidism

This is the connection most people miss. Thyrotropin-releasing hormone (TRH), elevated in primary hypothyroidism, is a direct prolactin secretagogue. Severe untreated hypothyroidism can produce prolactin elevations in the 1000–4000 mIU/L range and even, occasionally, mimic a prolactinoma on imaging via reactive lactotroph hyperplasia.

Always check TSH and free T4 in a hyperprolactinaemia workup. If hypothyroidism is found and corrected, the prolactin should track downward over 4–8 weeks. Cross-reading our thyroid panel interpretation guide alongside any prolactin abnormality is worth the ten minutes.

4. Physiological and other causes

• Pregnancy and lactation (covered above).
• Chest wall stimulation — surgical scars, herpes zoster, even tight clothing in some reports.
• Chronic kidney disease (reduced clearance).
• Cirrhosis.
• Polycystic ovary syndrome (modest elevation in a subset).
• Stress — physical or psychological.
• Idiopathic hyperprolactinaemia — the diagnostic residual after everything else has been excluded and imaging is clean. Often stable for years.

When to image

Endocrine Society guidance, set out by Melmed and colleagues in the 2011 NEJM/JCEM guidelines on the diagnosis and treatment of hyperprolactinaemia, remains the reference standard for imaging thresholds. In practice:

• Confirmed hyperprolactinaemia (two separate elevated samples) with macroprolactin excluded and no medication or hypothyroidism explanation → MRI pituitary with contrast.
• Prolactin >5000 mIU/L in the absence of pregnancy or medication cause → image regardless of symptoms.
• Persistent 2000–5000 mIU/L with symptoms → image.
• Persistent <2000 mIU/L with no symptoms and no clear cause → repeat surveillance is often reasonable before MRI.

A modest elevation with a large pituitary mass is the classical stalk-effect picture and suggests the mass is not the prolactinoma itself.

Symptoms — men versus women

Prolactin's reproductive footprint is to suppress GnRH pulsatility, which in turn suppresses LH and FSH, which suppresses gonadal steroid output. The downstream picture differs by sex.

In women

• Oligomenorrhoea or amenorrhoea — the most reliable early sign.
• Galactorrhoea — milky nipple discharge unrelated to pregnancy or lactation. Worth examining for, but absent in many women with hyperprolactinaemia.
• Anovulatory infertility.
• Reduced libido.
• Vaginal dryness, dyspareunia.
• Long-term: reduced bone mineral density from oestrogen deficiency.

Because the menstrual cycle is such a visible barometer, hyperprolactinaemia in pre-menopausal women is usually picked up relatively early.

In men

This is where the picture is often missed for years. Men don't have a monthly bleed to lose. The presentation is more insidious:

• Reduced libido.
• Erectile dysfunction.
• Infertility / reduced sperm count.
• Galactorrhoea — much rarer in men, but worth examining for.
• Gynaecomastia in a subset.
• Fatigue, reduced motivation, low mood — easy to write off as "stress" or "getting older."
• Long-term: secondary hypogonadism, with all its metabolic consequences.

Men presenting with low testosterone should have prolactin checked as part of the workup — there's no point pursuing testosterone replacement if a treatable prolactinoma is the driver. For the broader picture on male hormone interpretation, our piece on optimal testosterone ranges in men covers the downstream territory in detail.

The functional connections — dopamine, GH axis, fertility

Three connections are worth understanding properly.

Dopamine. Prolactin's tonic inhibitor is dopamine. Anything that depletes dopamine, blocks its receptors, or interrupts its delivery from the hypothalamus will raise prolactin. This is the mechanism behind antipsychotic-induced hyperprolactinaemia, and it's why dopamine agonists — cabergoline, bromocriptine — are the cornerstone of prolactinoma treatment. There's a fascinating body of research on dietary and botanical dopaminergic precursors and their effects on the broader axis; the mucuna pruriens and L-dopa dopamine research overview maps that literature.

Growth hormone axis. Lactotroph and somatotroph cells share the same pituitary lobe and a common developmental origin (Pit-1 lineage). Mixed mammosomatotroph tumours co-secrete prolactin and GH. More commonly: chronic hyperprolactinaemia from any cause suppresses GnRH and the gonadal axis, which interacts with the GH/IGF-1 axis through shared substrate and signalling pathways. Anyone tracking GH/IGF-1 status should have prolactin in the picture — our IGF-1 and HGH interpretation guide covers the somatotroph side in detail, and the specialist research peptide vendor catalogue lays out the broader IGF-1 / GH axis research-peptide landscape for those mapping the literature.

Fertility. The reproductive consequences of hyperprolactinaemia are entirely mediated through GnRH suppression. Once prolactin is normalised, the gonadal axis recovers — often quickly. This is why dopamine agonist treatment is so consistently effective at restoring fertility in prolactinoma.

Treatment overview — research framing

Standard treatment for symptomatic hyperprolactinaemia (and for prolactinomas of any size) is dopamine agonist therapy, usually cabergoline as first-line because of its tolerability and twice-weekly dosing. Bromocriptine is the older alternative, less well tolerated but cheaper and with the longest safety record (including in pregnancy).

Surgery (transsphenoidal resection) is reserved for cases that fail or don't tolerate medical therapy, or for macroadenomas with visual compromise. Radiotherapy is third-line.

For asymptomatic hyperprolactinaemia — particularly when due to a microprolactinoma in a post-menopausal woman with no bone density concerns — observation alone is often appropriate.

Active research is ongoing, with current trials registered through ClinicalTrials.gov covering everything from novel dopamine agonist formulations to the long-term consequences of medication-induced hyperprolactinaemia in psychiatric populations.

Pulling it together

A prolactin result is only as good as the conditions it was drawn under. Before any imaging cascade or referral, the questions to walk through are:

1. Was the sample drawn correctly? Mid-morning, fasted, after a rest period, no recent stress or breast stimulation?
2. Has macroprolactin been excluded? PEG precipitation if not.
3. Has medication review been done? Antipsychotics, antiemetics, opioids, oestrogens, verapamil?
4. Have TSH and free T4 been checked?
5. Is the magnitude consistent with the suspected cause? A 700 mIU/L reading is not a 5000 mIU/L reading; they're different problems.
6. Are there symptoms? Or is this an incidental elevation in an entirely well person?

Most modestly-elevated prolactins, sampled and reviewed properly, turn out to be either lab artefact, medication effect, or a manageable functional issue. The genuine prolactinomas are the minority — but they're the ones the careful workup is designed to catch.

This article is general educational information about laboratory test interpretation. It is not medical advice. Reference ranges vary by assay and laboratory; interpret your own results with the clinician who ordered them.